Asymmetric Dimethylarginine Determines the Improvement of Endothelium-Dependent Vasodilation by Simvastatin. Effect of Combination With Oral L-Arginine

Journal of the American College of Cardiology

Volumn 49, Issue 23, 2007, Pages 2274-2282

  Böger, Gerhild I ^a   Rudolph, Tanja K ^a,b   Maas, Renke ^a   Schwedhelm, Edzard ^a   Dumbadze, Ekaterina ^a   Bierend, Anneke ^a   Benndorf, Ralf A ^a   Böger, Rainer H ^a  

^a Clinical Pharmacology Unit   (Germany)

^b UNIVERSITY HEART CENTER HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ARGININE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CREATINE KINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; N(G),N(G) DIMETHYLARGININE; SIMVASTATIN; STATINE DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD LEVEL; BRACHIAL ARTERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CROSSOVER PROCEDURE; DRUG EFFECT; ENZYME INHIBITION; FEMALE; FLATULENCE; HUMAN; HUMAN EXPERIMENT; LOOSE FECES; MALE; MYALGIA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLEEP DISORDER; SUSTAINED RELEASE PREPARATION; ULTRASOUND; UPREGULATION; VASCULAR ENDOTHELIUM; VASODILATATION;

AGED; AGED, 80 AND OVER; ARGININE; C-REACTIVE PROTEIN; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE III; SIMVASTATIN; VASODILATION;

EID: 34249824593     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.02.051     Document Type: Article

References (39)

1. Laufs U., La Fata V., Plutzky J., and Liao J.K. Up-regulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97 (1998) 1129-1135
2. Endres M., Laufs U., Huang Z., et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 95 (1998) 8880-8885
3. Bates K., Ruggeroli C.E., Goldman S., and Gaballa M.A. Simvastatin restores endothelial NO-mediated vasorelaxation in large arteries after myocardial infarction. Am J Physiol 283 (2002) H768-H775
4. Scalia R., Gooszen M.E., Jones S.P., et al. Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice. Circulation 103 (2001) 2598-2603
5. Wilson S.H., Simari R.D., Best P.J., et al. Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering. Arterioscler Thromb Vasc Biol 21 (2001) 122-128
6. Treasure C.B., Klein J.L., Weintraub W.S., et al. Beneficial effect of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 332 (1995) 481-487
7. Guven G.S., Atalar E., Yavuz B., et al. Simvastatin treatment improves endothelial function and increases fibrinolysis in patients with hypercholesterolemia. J Natl Med Assoc 98 (2006) 627-630
8. Vita J.A., Yeung A.C., Winniford M., et al. Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. Circulation 102 (2000) 846-851
9. van Venrooij F.V., van de Ree M.A., Bots M.L., Stolk R.P., Huisman M.V., and Banga J.D. Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) study: a randomised, double-blind, placebo-controlled trial. Diabetes Care 25 (2002) 1211-1216
10. Michel T., and Feron O. Nitric oxide synthases: which, where, how, and why?. J Clin Invest 100 (1997) 2146-2152
11. Böger R.H. The emerging role of ADMA as a novel cardiovascular risk factor. Cardiovasc Res 59 (2003) 824-833
12. Surdacki A., Nowicki M., Sandmann J., et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 33 (1999) 652-658
13. Abbasi F., Asagmi T., Cooke J.P., et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 88 (2001) 1201-1203
14. Böger R.H., Bode-Böger S.M., Szuba A., et al. Asymmetric dimethylarginine: a novel risk factor for endothelial dysfunction. Its role in hypercholesterolemia. Circulation 98 (1998) 1842-1847
15. Böger R.H. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med 38 (2006) 126-136
16. Cooke J.P. Asymmetrical dimethylarginine: the über marker?. Circulation 109 (2004) 1813-1818
17. Böger R.H. Asymmetric dimethylarginine (ADMA) modulates endothelial function-therapeutic implications. Vasc Med 8 (2003) 149-151
18. Janatuinen T., Laakso J., Laaksonen R., et al. Plasma asymmetric dimethylarginine modifies the effect of pravastatin on myocardial blood flow in young adults. Vasc Med 8 (2003) 185-189
19. Corretti M.C., Anderson T.J., Benjamin E.J., et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. J Am Coll Cardiol 39 (2002) 257-265
20. Ribeiro Jorge P.A., Osaki M.R., and de Almeida E. Rapid reversal of endothelial dysfunction in hypercholesterolaemic rabbits treated with simvastatin and pravastatin. Clin Exp Pharmacol Physiol 24 (1997) 948-953
21. O'Driscoll G., Green D., and Taylor R.R. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within one month. Circulation 95 (1997) 1126-1131
22. Weis M., Pehlivanli S., Meiser B.M., and von Scheidt W. Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation. J Am Coll Cardiol 38 (2001) 814-818
23. Mohler E.R., Hiatt W.R., and Creager M.A. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 108 (2003) 1481-1486
24. Sheu W.H.H., Juang B.L., Chen Y.T., and Lee W.J. Endothelial dysfunction is not reversed by simvastatin in type 2 diabetic patients with hypercholesterolemia. Diabetes Care 22 (1999) 1224-1225
25. van de Ree M.A., Huisman M.V., de Man F.H., van der Vijver J.C., Meinders A.E., and Blauw G.J. Impaired endothelium-dependent vasodilation in type 2 diabetes mellitus and the lack of effect of simvastatin. Cardiovasc Res 52 (2001) 299-305
26. Vallance P., Leone A., Calver A., Collier J., and Moncada S. Accumulation of an endogenous inhibitor of NO synthesis in chronic renal failure. Lancet 339 (1992) 572-575
27. Simons L.A., Sullivan D., Simons J., and Celermajer D.S. Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia. Atherosclerosis 137 (1998) 197-203
28. Yamada M., Huang Z., Dalkara T., et al. Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment. J Cerebrovasc Blood Flow Metab 20 (2000) 709-717
29. Pereira E.C., Bertolami M.C., Faludi A.A., Salemi M., Bersch D., and Abballa D.S.P. Effects of simvastatin and L-arginine on vasodilation, nitric oxide metabolites and endogenous NOS inhibitors in hypercholesterolemic subjects. Free Radic Res 37 (2003) 529-536
30. Schulze F., Maas R., Freese R., Schwedhelm E., Silberhorn L., and Böger R.H. Determination of a reference value for N,N-dimethyl-L-arginine in 500 subjects. Eur J Clin Invest 35 (2005) 622-626
31. Lu T.M., Ding Y.A., Lin S.J., Lee W.S., and Tai H.C. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J 24 (2003) 1912-1919
32. Schnabel R., Blankenberg S., Lubos E., et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene study. Circ Res 97 (2005) e53-e59
33. Maas R., Dentz L., Schwedhelm E., et al. Elevated plasma levels of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) predict adverse events in patients undergoing noncardiac surgery. Crit Care Med (2006) In press.
34. G-dimethyl-L-arginine to L-citrulline in rats. Biochem Biophys Res Commun 148 (1987) 671-677
35. Takemoto M., and Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 21 (2001) 1712-1719
36. Joannides R., Haefeli W.E., Linder L., et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 91 (1995) 1314-1319
37. Corretti M.C., Plotnick G.D., and Vogel R.A. Technical aspects of evaluating brachial artery vasodilatation using high-frequency ultrasound. Am J Physiol 268 (1995) H1397-H1404
38. 15N-labeled nitrate by gas chromatography-mass spectrometry. Nitric Oxide 11 (2004) 1-8
39. Zoccali C., Bode-Böger S.M., Mallamaci F., et al. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase predicts mortality in end-stage renal disease (ESRD). Lancet 358 (2001) 2113-2117